Last reviewed · How we verify
Heraclin (BERGAPTEN)
Heraclin (generic name: BERGAPTEN) is a bergapten drug. It is currently in Phase 3 development.
Heraclin works by inhibiting the enzyme Cytochrome P450 1A1, which plays a role in the metabolism of various substances in the body.
Heraclin, also known as Bergapten, is a small molecule drug that targets Cytochrome P450 1A1. It belongs to the bergapten drug class, but its commercial status and approved indications are unknown. The mechanism of action and pharmacokinetic properties of Heraclin are also not well-documented. As a result, it is difficult to provide a comprehensive summary of this compound. Further research is needed to understand its potential therapeutic applications and safety profile.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | BERGAPTEN |
|---|---|
| Drug class | bergapten |
| Target | Taste receptor type 2 member 10, Cytochrome P450 1A1, Amine oxidase [flavin-containing] A |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | Phase 3 |
Mechanism of action
Think of Heraclin like a traffic cop that helps control the flow of chemicals in your body. By blocking the enzyme Cytochrome P450 1A1, Heraclin can affect how your body processes certain substances, which may help treat certain conditions. However, more research is needed to understand how this works and what effects it may have on the body.
Approved indications
Common side effects
Key clinical trials
- Fumaric Acid Ester-PUVA Therapy Versus Acitretin -PUVA Therapy in Pustular Palmoplantar Psoriasis (PHASE3)
- Comparison of UVA1 Phototherapy Versus Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Heraclin CI brief — competitive landscape report
- Heraclin updates RSS · CI watch RSS
Frequently asked questions about Heraclin
What is Heraclin?
How does Heraclin work?
What is the generic name of Heraclin?
What drug class is Heraclin in?
What development phase is Heraclin in?
What does Heraclin target?
Related
- Drug class: All bergapten drugs
- Target: All drugs targeting Taste receptor type 2 member 10, Cytochrome P450 1A1, Amine oxidase [flavin-containing] A
- Therapeutic area: All drugs in Metabolic
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing